Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2017—WaveSense introduced its nRichDX system for the bulk isolation of target cells and nucleic acids from liquid biopsies. The nRichDX uses the company’s proprietary paramagnetic bead technology to enable the capture of circulating tumor cells and cell-free DNA or cell-free RNA in quantities sufficient for analysis by next-generation sequencing and PCR techniques.
February 2017—Trovagene has entered into a long-term supply and distribution agreement with Boreal Genomics in which they will merge their respective technologies to co-develop urine and blood ctDNA assay kits. The companies intend to address an unmet need in the liquid biopsy testing market by providing a simple, routine, and low-cost urine and blood ctDNA assay for next-generation sequencing platforms run by laboratories of research institutions, cancer centers, and service facilities around the world.
February 2017—Qiagen launched the QIAseq cfDNA All-in-One kit, combining cell-free DNA extraction and library preparation in a dedicated solution for liquid biopsy analysis on next-generation sequencing platforms. The kit integrates with Qiagen’s PAXgene Blood ccfDNA tube as well as with the company’s bioinformatics workflow for cfDNA, creating a streamlined testing solution that aims to allow faster, more convenient, and reliable analysis of cell-free DNA from sample collection to interpreted result.
February 2017—Roche launched its Discovery 5-Plex procedure and reagents for immunohistochemistry research applications. This is the first pre-optimized, fully automated multiplex procedure available on the Ventana Discovery Ultra instrument.
February 2017—Meridian Life Science released a new brochure on its best performing tropical and vector-borne antigens and antibodies, including its new Zika reagents. Important troubleshooting tips are included for reducing cross-reactivity in flavivirus assays and increasing IgM detection sensitivity.
February 2017—Applied Spectral Imaging has entered into a collaboration with ARUP Laboratories to facilitate the development and commercialization of advanced digital pathology solutions, enhancing workflow efficiencies and simplifying the management and accessibility of clinical data.
February 2017—PerkinElmer’s Opal Multicolor Immunohistochemistry products for use with Leica Biosystems’ fully automated Bond RX research staining platform is now available. The kits can visualize up to six biomarkers and a nuclear counterstain on a single tissue section with next-day results.
January 2017—Ortho Clinical Diagnostics announced that the Food and Drug Administration has cleared its Vitros Automation Solutions for use with Ortho’s Vitros chemistry, immunodiagnostics, and integrated systems.
January 2017—Qiagen launched its QIAscout, a novel instrument for isolation of viable single cells from samples to enable single-cell analysis for next-generation sequencing, polymerase chain reaction, and other downstream applications.
January 2017—Hardy Diagnostics announced its new product, C Diff Banana Broth, which is recommended as a selective detection broth for the recovery of Clostridium difficile from environmental samples. Its name is derived from the color change reaction when C. diff is present; the broth changes from a deep red, indicating a negative reaction, to a milky yellow, indicating a positive reaction.
